LYT-200 now has gained fast track designation from the FDA in acute myeloid leukemia in addition to its prior designation for ...

Shares of PureTech Health plc (NASDAQ:PRTC – Get Free Report) were down 6.3% on Thursday . The stock traded as low as $17.04 and last traded at $17.55. Approximately 6,778 shares traded hands during ...

Single agent and combination data from Phase 1b AML/MDS trial presented at ASH 2024 showed potential of LYT-200 to serve broad range of patients across various lines of treatment LYT-200 is currently ...

The FDA has also granted orphan drug designation to LYT-200 for the treatment of AML as well as a separate Fast Track designation for the treatment of recurrent/metastatic head and neck squamous ...

BOSTON - PureTech Health plc (NASDAQ:PRTC, LSE:PRTC) has announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation to its investigational drug LYT-200 for the treatment ...

PureTech Health said the Food and Drug Administration granted fast-track designation for a drug candidate to treat patients with acute myeloid leukemia. The biotherapeutics company said the ...